← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleDiwakar DavarPhase 2

Domvanalimab (Domvanalimab)

Melanoma · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 2

Linvoseltamab (Linvoseltamab)

Food Allergy · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Monalizumab (Monalizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 23.9%임상시험 22상태 RECRUITING
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab [KEYTRUDA®])

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · Metastatic Cancer

#MetastaticCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 40%임상시험 22상태 DISCONTINUED
AntibodystaleJanssen Research & Development,…Phase 2

Cetrelimab (Cetrelimab)

Carcinoma, Non-Small-Cell Lung · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+4
효능 ORR 75%임상시험 20상태 RECRUITING
AntibodystaleJanssen Research & Development,…Phase 2

Bermekimab (Bermekimab)

Dermatitis, Atopic · Hidradenitis Suppurativa

#HidradenitisSuppurativa#Antibody#Phase2#항체#면역항체+4
효능 ORR 0%임상시험 19상태 DISCONTINUED
AntibodystaleEli LillyPhase 2

Cetuximab + Gemcitabine + Oxaliplatin (Cetuximab + Gemcitabine + Oxaliplatin)

Cholangiocarcinoma; Adenocarcinoma of Gallbladder · Unresectable

#Unresectable#Antibody#Phase2#항체#면역항체+4
효능 ORR 5%임상시험 19상태 ACTIVE
AntibodystaleRocheApproved

trastuzumab (Herceptin, Trastuzumab rezetecan)

HER2-positive Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#항체#면역항체+3
임상시험 19상태 RECRUITING
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Vibostolimab (Vibostolimab)

Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+3
효능 ORR 71.7%임상시험 19상태 RECRUITING
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 88.7%임상시험 18상태 RECRUITING
AntibodystaleRochePhase 1

Bevacizumab-IRDye800CW (Bevacizumab-IRDye800CW)

Adenomatous Polyposis Coli · Esophageal Cancer

#EsophagealCancer#Antibody#Phase1#항체#면역항체+3
임상시험 18상태 ACTIVE
AntibodystaleNeovii BiotechPhase 2

Catumaxomab (Catumaxomab)

Gastric Cancer; Gastric Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 18상태 ACTIVE
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Favezelimab (Favezelimab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 18상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Favezelimab/Pembrolizumab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 18상태 ACTIVE
AntibodystaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
임상시험 18상태 RECRUITING
AntibodystaleRochePhase 3

Rituximab and Hyaluronidase Human (Rituximab and Hyaluronidase Human)

Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 9%임상시험 18상태 RECRUITING
AntibodystaleBristol-Myers SquibbPhase 2

Urelumab (Urelumab)

Pancreatic Cancer · Malignant Tumors

#MalignantTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 5%임상시험 18상태 RECRUITING
AntibodystaleAmgenPhase 2

Panitumumab + paclitaxel (Panitumumab + paclitaxel)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 77.3%임상시험 17상태 ACTIVE
AntibodystaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
효능 ORR 67%임상시험 17상태 ACTIVE
AntibodystaleRochePhase 3

zanubrutinib, rituximab and lenalidomide (zanubrutinib, rituximab and lenalidomide)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+2
효능 ORR 45.7%임상시험 17상태 RECRUITING

12 / 92 페이지

← 이전다음 →